No biomarker
|
Malignant Pleural Mesothelioma
|
No biomarker
|
Malignant Pleural Mesothelioma
|
cisplatin + pemetrexed Sensitive: A1 - Approval
FDA - 2 days (NewA1)
|
cisplatin + pemetrexed Sensitive: A1 - Approval
FDA - 2 days - (New A1)
|
No biomarker
|
Malignant Pleural Mesothelioma
|
No biomarker
|
Malignant Pleural Mesothelioma
|
nivolumab + ipilimumab Sensitive: A1 - Approval
|
nivolumab + ipilimumab Sensitive: A1 - Approval
|
No biomarker
|
Malignant Pleural Mesothelioma
|
No biomarker
|
Malignant Pleural Mesothelioma
|
pemetrexed Sensitive: A1 - Approval
|
pemetrexed Sensitive: A1 - Approval
|
No biomarker
|
Malignant Pleural Mesothelioma
|
No biomarker
|
Malignant Pleural Mesothelioma
|
carboplatin + pemetrexed Sensitive: A2 - Guideline
|
carboplatin + pemetrexed Sensitive: A2 - Guideline
|
No biomarker
|
Malignant Pleural Mesothelioma
|
No biomarker
|
Malignant Pleural Mesothelioma
|
nivolumab Sensitive: A2 - Guideline
|
nivolumab Sensitive: A2 - Guideline
|
No biomarker
|
Malignant Pleural Mesothelioma
|
No biomarker
|
Malignant Pleural Mesothelioma
|
bevacizumab Sensitive: A2 - Guideline
|
bevacizumab Sensitive: A2 - Guideline
|
No biomarker
|
Malignant Pleural Mesothelioma
|
No biomarker
|
Malignant Pleural Mesothelioma
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
No biomarker
|
Malignant Pleural Mesothelioma
|
No biomarker
|
Malignant Pleural Mesothelioma
|
carboplatin + raltitrexed Sensitive: A2 - Guideline
|
carboplatin + raltitrexed Sensitive: A2 - Guideline
|
No biomarker
|
Malignant Pleural Mesothelioma
|
No biomarker
|
Malignant Pleural Mesothelioma
|
GC Sensitive: A2 - Guideline
|
GC Sensitive: A2 - Guideline
|
No biomarker
|
Malignant Pleural Mesothelioma
|
No biomarker
|
Malignant Pleural Mesothelioma
|
gemcitabine Sensitive: A2 - Guideline
|
gemcitabine Sensitive: A2 - Guideline
|
No biomarker
|
Malignant Pleural Mesothelioma
|
No biomarker
|
Malignant Pleural Mesothelioma
|
vinorelbine tartrate Sensitive: A2 - Guideline
|
vinorelbine tartrate Sensitive: A2 - Guideline
|
No biomarker
|
Malignant Pleural Mesothelioma
|
No biomarker
|
Malignant Pleural Mesothelioma
|
ramucirumab Sensitive: A2 - Guideline
|
ramucirumab Sensitive: A2 - Guideline
|
PD-L1 expression
|
Malignant Pleural Mesothelioma
|
PD-L1 expression
|
Malignant Pleural Mesothelioma
|
nivolumab Sensitive: C1 - Off-label
|
nivolumab Sensitive: C1 - Off-label
|
WT1 expression
|
Malignant Pleural Mesothelioma
|
WT1 expression
|
Malignant Pleural Mesothelioma
|
nivolumab + galinpepimut-S Sensitive: C3 – Early Trials
|
nivolumab + galinpepimut-S Sensitive: C3 – Early Trials
|
TMB-L
|
Malignant Pleural Mesothelioma
|
TMB-L
|
Malignant Pleural Mesothelioma
|
PD1 inhibitor Resistant: C3 – Early Trials
|
PD1 inhibitor Resistant: C3 – Early Trials
|
TMB-L
|
Malignant Pleural Mesothelioma
|
TMB-L
|
Malignant Pleural Mesothelioma
|
PD-L1 inhibitor Resistant: C3 – Early Trials
|
PD-L1 inhibitor Resistant: C3 – Early Trials
|
PD-L1 underexpression
|
Malignant Pleural Mesothelioma
|
PD-L1 underexpression
|
Malignant Pleural Mesothelioma
|
PD1 inhibitor Resistant: C3 – Early Trials
|
PD1 inhibitor Resistant: C3 – Early Trials
|
ERCC1 expression
|
Malignant Pleural Mesothelioma
|
ERCC1 expression
|
Malignant Pleural Mesothelioma
|
GC Sensitive: C3 – Early Trials
|
GC Sensitive: C3 – Early Trials
|
RRM1 expression
|
Malignant Pleural Mesothelioma
|
RRM1 expression
|
Malignant Pleural Mesothelioma
|
GC Sensitive: C3 – Early Trials
|
GC Sensitive: C3 – Early Trials
|
MSLN overexpression
|
Malignant Pleural Mesothelioma
|
MSLN overexpression
|
Malignant Pleural Mesothelioma
|
TC-210 Sensitive: C3 – Early Trials
|
TC-210 Sensitive: C3 – Early Trials
|
ASS1 mutation
|
Malignant Pleural Mesothelioma
|
ASS1 mutation
|
Malignant Pleural Mesothelioma
|
cisplatin + pemetrexed + pegargiminase Sensitive: C3 – Early Trials
|
cisplatin + pemetrexed + pegargiminase Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
Malignant Pleural Mesothelioma
|
PD-L1 overexpression
|
Malignant Pleural Mesothelioma
|
nivolumab Sensitive: C4 – Case Studies
|
nivolumab Sensitive: C4 – Case Studies
|
EML4-ALK I1171N + EML4-ALK L1196M
|
Malignant Pleural Mesothelioma
|
EML4-ALK I1171N + EML4-ALK L1196M
|
Malignant Pleural Mesothelioma
|
alectinib Resistant: C4 – Case Studies
|
alectinib Resistant: C4 – Case Studies
|